Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. Chief People Officer Samira Shaikhly reported an exercise-and-sale transaction in company stock. On June 12, 2026, she exercised options to acquire 6,250 shares of common stock at $11.70 per share, then sold 6,250 shares in an open-market transaction at a weighted average price of $35.0759 per share, with individual sale prices ranging from $35.00 to $35.19. These trades were executed under a pre-arranged Rule 10b5-1 sales plan. Following the transactions, she directly holds 793 shares of common stock and 23,750 stock options that remain outstanding and are scheduled to expire on August 6, 2035, continuing to give her equity exposure to Septerna’s future performance.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting an intended sale of 8,428 shares of Common Stock on 06/12/2026 arising from an exercise of stock options with cash used as the method of payment. The filing also lists recent 10b5-1 sales by Samira Shaikhly: 5,935 shares on 06/01/2026 and 11,798 shares on 05/26/2026.
Septerna, Inc.’s Chief People Officer Samira Shaikhly reported an exercise-and-sell sequence in company stock. She exercised options to acquire 5,935 shares of common stock at exercise prices of $1.55 and $2.76 per share, then sold 5,935 shares in open-market transactions at weighted average prices of $27.78, $28.79 and $29.66 per share, within ranges from $27.24 to $30.08. The sales were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025.
Septerna, Inc. Chief People Officer Samira Shaikhly reported an option exercise and related share sale. She exercised stock options to acquire 11,798 shares of common stock at an exercise price of $6.81 per share, then sold 11,798 shares in open-market transactions at a weighted average price of $30.0607 per share.
The sales were made under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025, and executed in multiple trades between $30.00 and $30.24 per share. After these transactions, she directly owned 793 shares of Septerna common stock.
SEPN submitted a Form 144 notice for a proposed sale of 11,798 shares tied to an exercise of stock options to be executed on 05/26/2026. The filing also discloses prior 10b5-1 sales by Samira Shaikhly of 70,453 shares on 03/02/2026 for $1,979,835.21.
The sale is reported through Morgan Stanley Smith Barney LLC with cash settlement; the excerpt shows a proceeds figure of $334,591.28 associated with the 11,798-share transaction. Transaction mechanics and timing are stated in the notice.
Septerna reported strong top-line growth for the three months ended March 31, 2026, with revenue of $26.5 million driven by its Novo Nordisk collaboration, compared with $0.2 million a year earlier. Revenue included recognition of upfront, research and milestone consideration under the agreement.
Research and development expense rose to $29.5 million and general and administrative expense to $10.3 million, reflecting pipeline expansion and public-company costs. Net loss narrowed to $8.6 million from $21.5 million, helped by collaboration revenue and $5.0 million of interest income.
Septerna ended the quarter with $522.1 million in cash, cash equivalents and marketable securities and deferred revenue of $152.0 million, and expects this liquidity to fund operations at least into 2029. The company also initiated a Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, with data anticipated in late 2026 or early 2027.
Septerna, Inc. reported first quarter 2026 results showing a sharp rise in collaboration revenue and a narrower loss as it advanced multiple clinical programs. Revenue was $26.5 million for the quarter ended March 31, 2026, driven by its Novo Nordisk partnership, compared to $0.2 million a year earlier.
Research and development expenses increased to $29.5 million and general and administrative expenses to $10.3 million, reflecting pipeline growth. Net loss improved to $8.6 million from $21.5 million, and cash, cash equivalents and marketable securities totaled $522.1 million, which the company expects will fund operations at least into 2029. Septerna highlighted positive Phase 1 data for SEP-631 in mast cell-driven diseases and the start of a Phase 1 trial for SEP-479 in hypoparathyroidism, alongside continued work on its TSHR NAM and Novo Nordisk collaboration programs.